Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.41 USD
-0.04 (-2.76%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $1.43 +0.02 (1.42%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLS 1.41 -0.04(-2.76%)
Will SLS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should Know
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for SLS
Solaris Resources Secures $54 Million in Funding
Solaris Closes $54 Million in Financing
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
Sellas Life Sciences announces initial data in Phase 2a trial of SLS009
Largest borrow rate increases among liquid names